Medical Health Cluster


Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China

Question  What are the 2-year health outcomes among patients hospitalized for COVID-19 in China? Findings  In this longitudinal cohort study that included 1864 patients, the most common symptoms at 2 years after SARS-CoV-2 infection were fatigue, chest tightness, anxiety, dyspnea, and myalgia, and most symptoms resolved from 1-year to 2-year follow-up, although […]

Read More

Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis

Abstract BACKGROUND Sabizabulin is an oral, novel microtubule disruptor that has dual antiviral and anti-inflammatory activities in preclinical models. METHODS A randomized, multicenter placebo-controlled phase 3 clinical trial was conducted with hospitalized patients with moderate to severe Covid-19 who were at high risk for acute respiratory distress syndrome (ARDS) and […]

Read More

Medically Ill Hospitalized Patients for COVID-19 Thrombosis Extended Prophylaxis With Rivaroxaban Therapy – MICHELLE

Contribution To Literature: The MICHELLE trial showed that rivaroxaban after hospitalization for COVID-19 improved clinical outcomes without increasing bleeding. Description: The goal of the trial was to evaluate rivaroxaban compared with control among patients discharged after hospitalization for coronavirus 2019 (COVID-19) infection. Study Design Randomization Parallel Participants discharged after COVID-19 […]

Read More

For Hospitalized Patients with COVID-19 Pneumonia, Tofacitinib May Be Beneficial

Compared with placebo, this Janus kinase inhibitor was associated with lower risk for death or respiratory failure in such patients. In patients hospitalized with COVID-19, excess inflammation generally underlies clinical progression. By reducing cytokine production, Janus kinase (Jak) inhibitors tamp down inflammation. Now, investigators report results of an industry-supported trial […]

Read More

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1–3). In an evaluation at 24 hospitals in 14 states,* the […]

Read More